References
- Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3–4):161–172.
- Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst. 2014 Mar;19(1):2–13.
- Rodríguez Y, Vatti N, Ramírez-Santana C, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8–37.
- Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):465–473.
- Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018 Dec 4;91(23):1051–1060.
- Koike H, Katsuno M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy. Neurol Ther. 2020 Dec;9(2):213–227.
- Lewis RA. Chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol. 2017 Oct;30(5):508–512.
- Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies. report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst. 2010 Sep;15(3):185–195.
- Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):981–987.
- Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):28–33.
- Hafsteinsdottir B, Olafsson E. Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: a population-based study in Iceland. Eur Neurol. 2016;75(5–6):263–268.
- Mengel D, Fraune L, Sommer N, et al. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018 Nov;58(5):681–687.
- Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2020 Jun 24;267:3094–3095.
- Centers for Disease Control and Prevention (CDC). International classification of diseases, ninth revision, clinical modification (ICD-9-CM). CDC; 2015 [cited 2021 Apr 12]. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm.
- Centers for Disease Control and Prevention (CDC). International classification of diseases, tenth revision, clinical modification (ICD-10-CM). CDC; 2020 [cited 2021 Apr 12]. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm
- Parliament of Spain, Law 14/2007, 3rd July, on biomedical research (BOE, 4 July 2007). Rev Derecho Genoma Hum. 2007 Jan-Jun;(26):283–325.
- Cea G, Idiáquez JF, Salinas R, et al. Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile. J Clin Neurosci. 2020 Apr;74:271–273.
- Laughlin RS, Dyck PJ, Melton LJ 3rd, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009 Jul 7;73(1):39–45.
- Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016 Sep-Oct;30(7):1401–1407.
- Rajabally YA, Peric S, Cobeljic M, et al. Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1100–1104.
- Doneddu PE, Cocito D, Manganelli F, et al. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092–1099.
- Ryan M, Ryan SJ. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care. 2018 Sep;24(17 Suppl):S371–S379.
- Rosier C, Graveline N, Lacour A, et al. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? Eur J Neurol. 2019 Apr;26(4):575–580.